Working… Menu

Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04784247
Recruitment Status : Recruiting
First Posted : March 5, 2021
Last Update Posted : July 9, 2021
Merck Sharp & Dohme Corp.
Parker Institute for Cancer Immunotherapy
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2024